Antisense activity against erbB-2 of a variety of sulfur-modified oligonucleotides was examined in a breast cancer cell line which overexpresses this oncogene. Using a 15 base anti-erbB-2 sequence previously shown to be effective, various backbone configurations containing phosphoromonothioate or phosphorodithioate linkages were evaluated for antisense activity by a two-color flow cytometric assay. This sequence was effective in inhibiting the production of erbB-2 protein when it was configured as a monothioate at each linkage and as an alternating dithioate/phosphodiester. Both of these compounds were also able to specifically inhibit erbB-2 mRNA expression, indicative of RNase H-mediated activity. The same sequence protected by either three dithioate or three monothioate linkages at each end was ineffective as an antisense reagent, suggesting that endonuclease activity is a significant determinant of the stability of oligonucleotides. Finally, the erbB-2 sequence target was shifted in an effort to improve antisense activity. A new lead sequence was identified that was significantly more effective in inhibiting erbB-2 protein levels and retained activity at lower concentrations.
INTRODUCTION
Antisense oligonucleotides have long held the potential to decrease the expression of a targeted gene by inhibiting transcription or translation and thereby achieve a phenotypic effect based upon expression of that gene. However, many of the effects achieved by these oligonucleotides may not be mediated by inhibition of the target gene (1, 2) . For both investigational and therapeutic applications, a number of obstacles must be overcome in order to both demonstrate and achieve specific inhibition in living cells: (i) the compounds must be delivered and maintained at a sufficient concentration and to an intracellular compartment that makes them available for interaction with their target; (ii) the oligonucleotides must have sufficient stability against exonucleases and endonucleases so that they can act catalytically; (iii) they must act in a sequence-specific manner to down-regulate only the gene that is targeted; (iv) the fraction of cells in a given population that receives the compound and demonstrates target downregulation must be defined.
The erbB-2 gene codes for a 185 kDa tyrosine kinase-linked transmembrane protein which is overexpressed in 30-50% of primary breast cancers (3) (4) (5) (6) . Overexpression, which is frequently due to gene amplification, is an early event in the development of many breast cancers and is maintained during invasion and metastatic progression of the disease (7) . Expression of erbB-2 is low in most normal adult tissues, making it an attractive therapeutic target (8) . We recently described a set of methods for delivering phosphorothioate oligonucleotides and measuring antisense activity against the human erbB-2 oncogene in breast cancer cells (9) . Antisense oligonucleotides or control sequences are co-delivered to cells with a fluorescent-tagged oligonucleotide using cationic liposome-mediated transfer. A high concentration of the fluorescent tracer and non-tagged oligonucleotide rapidly accumulate in the nucleus. Cells receiving the co-delivered oligonucleotides can then be identified, quantitated, immunostained for level of the antisense target protein and physically sorted to measure RNA levels and phenotypic changes. Because flow cytometric analysis is quantitated on a per cell basis, simultaneous two-color analysis of the tagged oligonucleotide (a measure of dose) versus immunodetection of the targeted gene product yields a dose-response curve for a given antisense compound.
Unmodified DNA oligomers form stable duplexes with RNA, direct RNase H activity and have relatively few non-specific effects. However, they are extremely susceptible to degradation by exo-and endonucleases. Therefore, a number of different modified oligonucleotides designed to be more resistant to *To whom correspondence should be addressed. Tel: +1 919 684 6133; Fax: +1 919 681 6291; Email: jrm@galactose.mc.duke.edu Nucleic Acids Research, 1996, Vol. 24, No. 22 4559 nucleases have been tested for their efficacy as antisense compounds. These include methylphosphonates (10), phosphorothioates (11), propynes (12) , phosphoramidates (13) and alkylphosphotriesters (14) . We have been investigating a series of compounds that have either one (phophorothioate, PS) or both (phosphorodithioate, PS2) of the non-bridging oxygen atoms in the internucleotide phosphodiester group replaced by sulfur. PS oligonucleotides are the most commonly used antisense compounds, while little biological information is currently available on PS2 oligonucleotides. Different configurations of PS2 and PS oligonucleotides were compared using our assay system. We provide evidence that PS2 oligonucleotides may direct RNase H-mediated cleavage of sequence-specific RNA targets in vivo. In addition, we have screened a series of sequences near the start site of translation in the erbB-2 gene. Dramatically different antisense effects were observed both with different backbone configurations and different sequences.
MATERIALS AND METHODS

Oligonucleotide synthesis
Antisense and scrambled control phosphorothioate and phosphorodithioate oligonucleotides were synthesized on an ABI 380B DNA synthesizer (Perkin Elmer) as previously described (15, 16) . After synthesis, oligomers were purified by HPLC and purity was ensured by collection of a single peak. 31 P-NMR was performed on all syntheses to verify that thioate or dithioate linkages were >95% of the total. A fluorescein 5′-end-labeled phosphorothioate oligomer (TCT CTC TCT CTT TTT) was obtained from Research Genetics. Oligomers were diluted to a concentration of 20 µM, filter sterilized and stored frozen in distilled water. We have observed no evidence of degradation or loss of antisense activity with oligomers stored in this way over the course of a 10 month period.
Cell culture and liposome-mediated delivery
SK-BR-3 cells were obtained from the American Type Culture Collection and maintained in RPMI 1640 containing 10% heat-inactivated fetal bovine serum (FBS). For liposome delivery, cells were preincubated in serum-free medium (Opti-Mem I; Gibco BRL). For a typical experiment, oligonucleotides were added to Lipofectin (Gibco BRL) yielding final concentrations of 0.3 µM test oligomer, 0.05 µM fluorescein oligomer and 10 µg/ml Lipofectin. Liposome-oligomer solutions were incubated for 30 min at room temperature and then added at a volume of 0.3 ml/16 mm tissue culture well. Cells were incubated with the liposome solution for 4 h, after which RPMI containing 10% FBS was added to stop uptake of liposomes.
ErbB-2 protein detection and flow cytometry
Immunofluorescent detection of cell surface receptors was performed as previously described (9) . Briefly, cells were treated with 0.25% trypsin, 1 mM EDTA, counted and aliquoted at ∼50 000 cells/well into 96-well plates. Cells were pelleted at 2000 g at 5_C, washed twice in ice-cold azide wash buffer (phosphate-buffered saline, 0.5% FBS, 0.1% azide) and then resuspended in 100 µl 1% bovine serum albumin (BSA) containing the erbB-2 mouse monoclonal antibody TA-1 (Oncogene Science) at 0.25 µg/ml. Cells were incubated on ice for 1 h, washed three times in azide wash buffer, then incubated on ice in 1% BSA containing R-phycoerythrin-labeled goat anti-mouse conjugated (Molecular Probes) secondary antibody at 10 µg/ml for 1 h. Cells were washed and then analyzed by flow cytometry on a Becton Dickinson FACStar Plus. For physically sorting populations, cells were trypsinized, pelleted and brought up to a final concentration of 2 × 10 6 /ml in RPMI plus 20% FBS, then sorted by fluorescein content in a Becton Dickinson FACStar Plus flow cytometer at an average flow rate of 2000 cells/s.
Northern blotting
After sorting cells based upon the level of the fluorescent tracer, total RNA was extracted by the guanidium thiocyanate method (17) . RNA was electrophoresed, blotted and probed for erbB-2 as previously described (18) . Densitometry of short exposure autoradiograms was performed to quantitate the amount of hybridization. 
Immunoprecipitation
Radioimmunoprecipitations were performed as previously described (19) . Briefly, cells were treated with oligomers complexed with cationic liposomes and then labeled with 50 µCi/ml [ 35 S]methionine in methionine-free RPMI for 3 h. Extracts were prepared by NP-40 lysis and sonication and protein concentrations quantitated by the Bradford Assay (BioRad). Equal amounts of protein were precleared with protein G-Sepharose (Pharmacia) and then reacted with a combination of 1 µg anti-erbB-2 antibody TA-1 (Oncogene Science) and 1 µg anti-proliferating cell nuclear antigen (PCNA) monoclonal antibody (Dako). The immune complexes were recovered by binding to protein G-Sepharose, washed, boiled in SDS sample buffer and then electrophoresed by 7.5% SDS-PAGE. Gels were fixed, dried and the signals quantitated by analysis on a Molecular Dynamics PhosphorImager. The negative control for immunoprecipitation was performed with 2 µg/ml mouse IgG (Coulter Immunology). Results are reported as a ratio between the erbB-2 and PCNA signals.
RESULTS
Antisense effects by variations of the thioated backbone
We previously identified a lead sequence for down-regulating the erbB-2 oncogene in the SK-BR-3 human breast cancer cell line (9) . The erbB-2 gene is amplified in this cell line ∼16-fold and the protein is overexpressed compared with normal mammary epithelial cells by a factor of ∼100 (20) . This sequence targets the AUG initiation codon of the erbB-2 gene and has been designated US-1 (Table 1) . We have used a scrambled US-1 sequence as a specific control for this compound, designated US-D. The US-1 sequence was synthesized with the following configurations for antisense testing (Table 2) After densitometry through three different points of the hybridizing bands, normalization to the GAPDH signal shows that a 5-to 10-fold reduction in erbB-2 mRNA is achieved by both of these compounds in the high fluorescent window, consistent with the protein data ( Fig. 1) and an RNase H mode of action.
control sequence was also synthesized with all monothioate, all dithioate, alternating monothioate and alternating dithioate configurations. We tested the relative efficacy of these sequences for downregulating erbB-2 using a two-color flow cytometric assay (9) . This method takes advantage of co-delivery, via cationic liposome-mediated transfection, of a tracer oligonucleotide that is fluoresceinated at the 5′-end (sequence in Table 1 ). This allows us to identify and quantitate cells that receive varying doses of the tracer and unlabeled antisense oligonucleotides. We have previously shown that treatment of these cells with cationic liposomes plus the fluorescent tracer oligonucleotide does not affect the level of erbB-2 cell surface protein (9) . By both fluorescence microscopy and flow cytometry we have observed that the tracer rapidly accumulates in the nucleus, while very little fluorescence is associated with the cell membrane. The highest levels of nuclear fluorescence are observed shortly after the 4 h liposome treatment. There is a steady decline in both the intensity and frequency of cells with nuclear fluorescence, so that by 96 h few cells have detectable levels. While small oligonucleotides can rapidly diffuse into the nucleus of dead cells, the vast majority of cells treated in this manner with nuclear fluorescence are alive, as determined by dye exclusion, their light scattering properties as measured by flow cytometry and the continued viability of these cells after flow cytometric sorting. Most importantly, nuclear fluorescence coincided with erbB-2 down-regulation at the protein and RNA levels (9).
The antisense compounds with different backbone configurations were delivered at a 6:1 ratio (antisense:tracer) to SK-BR-3 cells. After a 48 h incubation, cell surface erbB-2 protein was detected by indirect immunofluorescence using an anti-erbB-2 monoclonal antibody. The flow cytometric analysis of this experiment is shown in Figure 1A , with the amount of fluorescent tracer increasing on the x-axis and erbB-2 quantitated by binding of the phycoerythrin-conjugated secondary antibody on the y-axis. Significantly decreased erbB-2 protein levels were observed using only the full monothioate (US-1 S) and the alternating dithioate (US-1 S2O2) compounds. This is represented by the number of cells in the lower right quadrant of these two-dimensional plots, i.e. high levels of tracer and low levels of erbB-2. The alternating monothioate (SO) and both the capped monothioate and dithioate (S-CAP and S2-CAP) failed to reduce the levels of cell surface erbB-2 protein in this assay. Results from three separate experiments were quantitated and are plotted in Figure 1B . For this analysis, the level of erbB-2 protein was compared not only between different backbones but also between the high and low fluorescent fractions for each compound. Again, only the S and S2O2 US-1 compounds significantly down-regulated the steady-state levels of erbB-2 protein in the high fluorescent fraction.
The full dithioate compound (S2) was not effective using this method. In no instance did we observe intracellular accumulation of the tracer oligonucleotide or down-regulation of erbB-2 using this compound (data not shown). This was reflected in the relative percentage of cells containing high or low levels of the tracer oligonucleotide (Fig. 1C) . Forty eight hours after delivery of the different backbones, the percentage of cells containing over a threshold level of tracer (high fluorescent) varied between 40 and 60% of the lipofected culture. In general, cells receiving monothioates contained higher levels of tracer oligonucleotide than those receiving dithioated DNA. However, there were virtually no cells that contained a significant level of fluorescence when co-lipofected with the S2 compound, even when the cells were examined immediately after the 4 h lipofection procedure. Given this apparent failure of delivery, the full dithioate compounds were eliminated from further analysis in this study.
The alternating dithioate (S2O2) US-1 sequence appeared to work as well as the all monothioate sequence (S), as measured by the decrease in steady-state levels of the erbB-2 protein. In order to confirm that these compounds were specifically inhibiting erbB-2 mRNA, we used the fluorescent tracer compound and flow cytometry to physically sort cells 24 h after lipofection into low and high fluorescent fractions. Total cellular RNA extracted from these cells was hybridized with an erbB-2 cDNA probe followed by a probe for the GAPDH gene to control both for RNA loading and non-specific inhibition of RNA levels ( Fig. 2A) . Hybridization to erbB-2 was quantitated and normalized to the signal for GAPDH (Fig. 2B) . Specific and potent inhibition of the erbB-2 mRNA was seen in the high fluorescent fraction for both the US-1 S2O2 and S sequences compared with both the low fluorescent fractions and with the high fluorescent fraction of the scrambled control sequences (US-D). The alternating dithioate yielded an ∼10-fold reduction compared with a 5-fold reduction in erbB-2 mRNA achieved by the all monothioate antisense compound. This experiment indicates that the S2O2 backbone can specifically inhibit an RNA target, likely through the activity of RNase H, with at least the same efficiency as the all monothioate sequence.
Effect of sequence variations
The US-1 sequence is 15 bases long and targets the start of erbB-2 translation (Table 1 and Fig. 3 ). This sequence was chosen from an initial series of sequences that included the start of transcription and the intron 1 splice donor and acceptor sites as other targets (J.P.Vaughn, unpublished data). Extensive testing of the US-1 sequence showed that it consistently inhibited the steadystate levels of erbB-2 and led to an accumulation of cells in the G1 phase of the cell cycle (9) . Since choosing the best sequence is largely an empirical exercise, we systematically began to shift the target upstream and downstream (in 3 base increments, all monothioates) in an effort to improve the antisense effect (Table  1 and Fig. 3 ). This series of sequences was tested in triplicate lipofections and compared with US-1 by flow cytometry in SK-BR-3 cells (Fig. 4A and B) . Each of the antisense sequences inhibited erbB-2 protein levels, but with widely varying potency. The two compounds that target sequences 5′ of US-1 (US-3 and UT-1) were more efficient than the 3′ targets (US-4 and US-5). The flow cytometric analysis yields a dose-response curve in a single step, i.e. erbB-2 levels and the amount of fluorescent tracer are measured on a per cell basis. Down-regulation at lower tracer levels is indicative of more effective antisense compounds. In particular, the US-3 sequence achieved more erbB-2 inhibition than US-1 and at a lower dose. This can be seen in the flow analysis, with more cells having a decreased erbB-2 content (y-axis) at lower x-axis values. This result was highly reproducible in a number of different experiments. The UT-1 sequence also performed slightly better than US-1. The relative activity of the US-3 versus US-1 sequences was also compared in another erbB-2 gene-amplified cell line, SK-OV-3, derived from an epithelial ovarian cancer. Similar results were obtained, with US-3 having greater antisense activity than US-1 (data not shown).
To further characterize and compare the relative efficiencies of the US-1 and US-3 sequences, we measured their effects on de novo erbB-2 protein synthesis at varying doses. SK-BR-3 cells were lipofected with the antisense compounds US-1 and US-3 (and their cognate scrambled controls US-D and SC-3 respectively). At 12 h after lipofection, the cells were labeled for 1 h with [ 35 S]methionine. Protein extracts were prepared and an immunoprecipitation performed using both an anti-erbB-2 and an anti-PCNA antibody (Fig. 5A) . Phosphorimage quantitation of the specifically immunoprecipitating bands was obtained and the erbB-2 signal was normalized to the level of PCNA in each lane. This ratio was then compared with the erbB-2:PCNA ratio obtained using the scrambled control compounds (expressed as percent of control in Fig. 5B ). While US-1 was only effective at 0.3 µM (the dose used in all previous experiments), US-3 continued to inhibit erbB-2 protein synthesis at the lowest concentration used (0.075 µM). This is consistent with the flow cytometric data, which also indicated that US-3 was effective at lower doses, i.e. at lower intracellular tracer concentrations.
DISCUSSION
Our goal is to identify effective antisense compounds targeted to the erbB-2 oncogene, which is amplified and overproduced in a large fraction of breast and other epithelial cancers (3, 21, 22) . To this end, we have developed a rapid and sensitive assay to monitor, in cell culture, the relationship between intracellular oligomer concentration and down-regulation of the target gene (9) . Using this assay, we have explored the effect of different sulfur-containing backbone modifications and different sequence targets on inhibition of erbB-2.
We tested novel backbone configurations using combinations of phosphorodithioate and phosphodiester linkages. Oligonucleotides with these linkages do not have the additional chiral center resulting in the numerous potential diastereomers characteristic of monothioate-substituted oligomers. This stereospecificity enhances the stability of dithioate-DNA complexes compared with monothio-substituted oligonucleotides (23) . In addition, the dithioated backbone is stable to exo-and endonucleases and can direct RNase H-mediated degradation of target RNA using HeLa cell nuclear extracts (23) . Examining the different backbone configurations with the same sequence, we found that an alternating phosphodithioate/phosphodiester configuration was as effective as monothioate linkages at each position in achieving gene-specific down-regulation. The alternating dithioate specifically reduced erbB-2 mRNA, providing further evidence that this backbone can direct RNase H activity (23). Ghosh et al. reported that dithioate-containing (at every linkage) oligomers were as unstable as unmodified DNA in nuclear extracts prepared from a breast cancer cell line (24) . The current study and previous results (23) indicate that a phosphorodithioate at every other linkage is sufficient to protect these oligomers from both exo-and endonuclease activity in the nucleus and cytoplasm. The measured instability of these compounds found by Ghosh et al. may have been due to the use of 5′-labeled oligomers, where dephosphorylation can be interpreted as degradation.
Other dithioate backbone configurations were also tested in the current study. The same anti-erbB-2 sequence containing three dithioate linkages at each end (capped) was ineffective in reducing steady-state levels of erbB-2 protein. These capped compounds were designed to be resistant to exonucleolytic activity, which appears to be the primary type of nuclease present in cell extracts and serum (25, 26) . Since both the monothioate and dithioate capped compounds had no measurable antisense activity on the steady-state levels of the erbB-2 protein, we conclude that significant endonuclease activity is also present. By measuring de novo erbB-2 protein synthesis at 12 and 24 h after delivery we were able to show a small degree of specific inhibition only at 12 h using the capped compounds (data not shown). This result is consistent with relatively rapid degradation of this configuration. The alternating dithioate and full monothioate oligomers were active at both time points in this same assay.
Comparable antisense activity was observed with the full monothioate and alternating dithoate compounds, however, we were able to improve on this activity by altering the sequence target. We are currently formulating the improved sequence in the alternating dithioate backbone and testing the efficacy of these compounds in inhibiting the growth of breast and ovarian cancer xenografts that overproduce the erbB-2 protein, both with and without liposome-mediated delivery. Our experiments suggest that there might be a relatively narrow window for optimal antisense effect on erbB-2. However, animal experiments have frequently demonstrated more robust biological effects than would be predicted in tissue culture. Given the difficulty of examining antisense effects in animals, our test system provides a measure of confidence that observed biological effects may be due to antisense inhibition of the targeted gene.
